Compare · CV vs MASI
CV vs MASI
Side-by-side comparison of CapsoVision Inc. (CV) and Masimo Corporation (MASI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CV and MASI operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MASI is the larger of the two at $9.32B, about 30.8x CV ($302.5M).
- Over the past year, CV is up 51.0% and MASI is up 9.0% - CV leads by 42.0 points.
- MASI has been more active in the news (3 items in the past 4 weeks vs 2 for CV).
- MASI has more recent analyst coverage (24 ratings vs 2 for CV).
- Company
- CapsoVision Inc.
- Masimo Corporation
- Price
- $6.05+5.03%
- $178.65-0.03%
- Market cap
- $302.5M
- $9.32B
- 1M return
- -27.49%
- +0.32%
- 1Y return
- +51.00%
- +9.00%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2007
- News (4w)
- 2
- 3
- Recent ratings
- 2
- 24
Masimo Corporation
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. The company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. The company offers coronavirus-2019 response and telehealth solutions; connectivity devices; and nasal high flow ventilation and neuromodulation solutions. The company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, physician offices, long term care facilities, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. Incorporated in 1989, the company is headquartered in Irvine, California.
Latest CV
- SEC Form EFFECT filed by CapsoVision Inc.
- SEC Form S-1 filed by CapsoVision Inc.
- SEC Form 3 filed by new insider Shen Ching Hang
- SEC Form 3 filed by new insider Harari Eliyahou Et Al
- SEC Form 10-K filed by CapsoVision Inc.
- CapsoVision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- CapsoVision Reports Fourth Quarter and Full Year 2025 Financial Results
- SEC Form 4 filed by Tsai Chen Lung
- SEC Form 4 filed by Kuo Hui Ying
- SEC Form 4 filed by King Wen-Herng Henry
Latest MASI
- SEC Form DEFA14A filed by Masimo Corporation
- Masimo Corporation filed SEC Form 8-K: Other Events
- Telix Strengthens Board with Additional Director Appointments
- SEC Form DEFM14A filed by Masimo Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Masimo Corporation
- Masimo downgraded by Raymond James
- SEC Form PREM14A filed by Masimo Corporation
- CEO Szyman Catherine M. covered exercise/tax liability with 1,069 shares and converted options into 2,101 shares, increasing direct ownership by 16% to 7,605 units (SEC Form 4)
- EVP & Chief Financial Officer Young Micah W converted options into 873 shares and covered exercise/tax liability with 471 shares, increasing direct ownership by 2% to 25,656 units (SEC Form 4)
- SEC Form 4 filed by Director by deputization Politan Capital Management Lp